Personalized medicine for non-small-cell lung cancer
Publication in refereed journal


香港中文大学研究人员 ( 现职)

龙浩锋教授 (肿瘤学系)

莫树锦教授 (肿瘤学系)

全文

数位物件识别号 (DOI) http://dx.doi.org/10.1586/ERA.10.76

引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/11WOS source URL

其它资讯

摘要Non-small-cell lung cancer (NSCLC) is a heterogeneous illness associated with a high mortality rate. Personalized therapy may improve treatment outcomes by identification of a specific genotypic anomaly and target-specific therapy. The most significant development in recent years was the discovery of activated EGF receptor (EGFR) mutations at exons 19 and 21. Patients with EGFR mutations respond dramatically to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib, resulting in longer progression-free survival. Multiple randomized studies, including the Iressa Pan-Asia Study and WJTOG3405, have confirmed the role of EGFR tyrosine kinase inhibitors as standard first-line therapy for patients with the EGFR mutation. In this article, we summarize the current nonpersonalized therapies and examine the available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, or metastatic disease.

着者Mok TS, Zhou Q, Leung L, Loong HH
期刊名称Expert Review of Anticancer Therapy
出版年份2010
月份10
日期1
卷号10
期次10
出版社EXPERT REVIEWS
页次1601 - 16http://aims.cuhk.edu.hk/converis/portal/Publication/11
国际标準期刊号1473-7140
电子国际标準期刊号1744-8328
语言英式英语

关键词epidermal growth factor; erlotinib; gefitinib; individualized medicine; non-small-cell lung carcinoma; receptor; receptor protein tyrosine kinases
Web of Science 学科类别Oncology; ONCOLOGY